Table 4 DFS by MMR and neoadjuvant radiotherapy status in univariable and multivariable analysis adjusted for clinical characteristics.

MMR and NRT status	No. of patients (n = 1015)	5-year rate (%)	Univariable	Multivariable
MMR and NRT status	No. of patients (n = 1015)	5-year rate (%)	P value^a	HR	95% CI	P value^b
NCRT	591
dMMR	45	41	0.070	1.495	0.916–2.444	0.108
pMMR	546	66
NCT	424
dMMR	21	92	0.020^*	0.117	0.016–0.847	0.034^*
pMMR	403	59
dMMR	66
NCRT	45	41	0.036^*	10.580	1.333–83.974	0.026^*
NCT	21	92
pMMR	949
NCRT	546	66	0.033^*	0.763	0.587–0.991	0.043*
NCT	403	59

DFS disease-free survival, dMMR deficient mismatch repair, pMMR proficient mismatch repair, NRT neoadjuvant radiotherapy, NCT neoadjuvant chemotherapy, NCRT neoadjuvant chemoradiotherapy, HR hazard ratio, CI confidential interval.
*Statistically significant.
^aUnivariable survival between these subgroups was compared by using the log-rank test.
^bCox proportional-hazards regression analysis, which adjusted for clinicopathologic covariates (including age, gender, clinical T or N stage, localization, and neoadjuvant radiotherapy) were used to calculate P values.

Quick links

Search